Flu Shot Crucial for Heart Disease Patients, Study Shows

For individuals living with atherosclerotic cardiovascular disease (ASCVD), the influenza virus poses a significantly heightened risk, extending far beyond a typical seasonal illness. Recent research underscores the critical importance of annual flu vaccination for this vulnerable population, and highlights a concerning trend: many with heart disease still forgo this vital preventative measure.

The Link Between Heart Disease and the Flu

Influenza isn’t just a respiratory infection. it can exacerbate existing cardiovascular conditions and even trigger acute cardiac events. The risk of ASCVD associated with influenza is considerably high, particularly among middle-aged working adults ¹. Hospitalization due to the flu increases the risk of severe clinical outcomes in adults with pre-existing ASCVD ².

Flu Vaccination Rates Remain Low Among Those With Heart Disease

Despite the clear risks, flu vaccination rates among adults with heart disease remain suboptimal. More than one in three adults with heart disease skip the annual flu shot, and disparities in access and awareness contribute to this gap ³.

The Connection to Lipid-Lowering Therapy

Interestingly, research suggests a correlation between influenza vaccination status and the use of lipid-lowering therapies (LLTs). A study analyzing data from the Behavioral Risk Factor Surveillance System (BRFSS) found that American adults with ASCVD who are unvaccinated for influenza have lower odds of utilizing LLTs ⁴. Specifically, unvaccinated individuals had a 46% lower likelihood of using LLTs, even after accounting for factors like demographics, comorbidities, healthcare access, and other cardiovascular medication use.

Study Details

• The study pooled data from 2017, 2019, and 2021.
• It included 66,923 participants aged 40-75 with self-reported ASCVD.
• 55% of participants reported receiving an influenza vaccination in the past year.
• 76% reported using lipid-lowering therapies.

Why This Matters

The association between flu vaccination and LLT use suggests that individuals who are hesitant to receive one preventative therapy may be less likely to engage in others. This highlights the potential role of addressing misinformation and promoting comprehensive preventative care strategies for those with ASCVD.

Key Takeaways

• Individuals with ASCVD are at higher risk of severe complications from the flu.
• Flu vaccination is a critical preventative measure for those with heart disease.
• There is a concerning gap in flu vaccination rates among this population.
• Unvaccinated individuals with ASCVD may be less likely to utilize lipid-lowering therapies.

Protecting cardiovascular health requires a multi-faceted approach, and annual influenza vaccination is a cornerstone of that strategy. Continued efforts to improve vaccination rates and address barriers to preventative care are essential for reducing the burden of cardiovascular disease.